{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:53:13Z","timestamp":1793040793708,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.1001\/jamadermatol.2022.1185","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T11:43:07Z","timestamp":1652269387000},"page":"735","source":"Crossref","is-referenced-by-count":64,"title":["Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis"],"prefix":"10.1001","volume":"158","author":[{"given":"Kenneth B.","family":"Gordon","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[{"name":"Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Dermatology Clinical Research, Henry Ford Health System, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Wixted","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Cross","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Deherder","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi220019r1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis.","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"doi220019r2","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis.","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"doi220019r3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.","volume":"9","author":"Strober","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"doi220019r4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology.","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220019r6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"doi220019r7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"doi220019r8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials.","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"doi220019r9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.","volume":"82","author":"Reich","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220019r10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"doi220019r11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.v34.6","article-title":"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.","volume":"34","author":"Reich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi220019r12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure.","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"14","key":"doi220019r13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis.","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"doi220019r14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.v83.5","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"doi220019r15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"doi220019r16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F.","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"issue":"10273","key":"doi220019r17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"doi220019r18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"doi220019r19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"doi220019r20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis.","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"doi220019r21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi220019r22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220019r23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members.","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity"},{"issue":"2","key":"doi220019r24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4049\/jimmunol.1202924","article-title":"Cutting edge: IL-17\u2013secreting innate lymphoid cells are essential for host defense against fungal infection.","volume":"190","author":"Gladiator","year":"2013","journal-title":"J Immunol"},{"key":"doi220019r26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.v186.4","article-title":"Bimekizumab for the treatment of moderate to severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase 2a randomized, multicenter double-blind study.","author":"Oliver","journal-title":"Br J Dermatol"},{"issue":"20","key":"doi220019r27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"doi220019r28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"doi220019r29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis.","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"issue":"6","key":"doi220019r30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort.","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi220019r31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"7","key":"doi220019r32","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"doi220019r33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi220019r34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"issue":"9","key":"doi220019r35","article-title":"IL-17 cytokines in immunity and inflammation.","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"doi220019r36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"doi220019r37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40257-016-0206-4","article-title":"A clinician\u2019s guide to the diagnosis and treatment of candidiasis in patients with psoriasis.","volume":"17","author":"Armstrong","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"doi220019r38","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies.","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi220019r39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jdermsci.2020.12.003","article-title":"Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections.","volume":"101","author":"Hiruma","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"12","key":"doi220019r40","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi220019r41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","article-title":"Incidence and risk of inflammatory bowel disease in patients with psoriasis\u2014a nationwide 20-year cohort study.","volume":"139","author":"Egeberg","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi220019r42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study.","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"doi220019r43","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.7573\/17404398","article-title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.","volume":"9","author":"Fieldhouse","year":"2020","journal-title":"Drugs Context"},{"issue":"1","key":"doi220019r44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","article-title":"Crohn\u2019s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.","volume":"19","author":"Smith","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"doi220019r45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.23736\/S0392-0488.18.06112-6","article-title":"Suicidality among psoriasis patients: a critical evidence synthesis.","volume":"154","author":"Wu","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"issue":"7","key":"doi220019r46","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jdv.2017.31.issue-7","article-title":"The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis.","volume":"31","author":"Wu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi220019r5","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis, 2004. Accessed March 31, 2022. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-indicated-treatment-psoriasis"},{"key":"doi220019r25","unstructured":"ClinicalTrials.gov. A study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in adult patients with chronic plaque psoriasis. 2017. March 31, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03230292"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2791835\/jamadermatology_gordon_2022_oi_220019_1657583981.95879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T11:07:13Z","timestamp":1658315233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2791835"}},"subtitle":["Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.1185","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}